Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Neuroscience Letters

• Publication date

  1995-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0304-3940(95)12137-SPMID 8830323
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures.

  1995cited by this paper
• Comparative study of voltage-sensitive sodium channel blockers in focal ischaemia and electric convulsions in rodents.

  1994cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline protects against both AMPA and kainate-induced lesions in rat striatum in vivo.

  1994cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum.

  1993cited by this paper
• Neuropharmacology of quinolinic and kynurenic acids.

  1993cited by this paper
• Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.

  1992cited by this paper
• Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones.

  1992cited by this paper
• Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection.

  1991cited by this paper
• Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids.

  1991cited by this paper
• Lamotrigine protects against kainate but not ibotenate lesions in rat striatum.

  1990cited by this paper
• Neuroprotective effects of MK-801 in vivo: selectivity and evidence for delayed degeneration mediated by NMDA receptor activation

  1988cited by this paper
• The glutamate antagonist MK‐801 reduces focal ischemic brain damage in the rat

  1988cited by this paper
• MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period.

  1988cited by this paper
• Patterns of cell loss in Huntington's disease

  1987cited by this paper
• Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

  1986cited by this paper
• Selective sparing of a class of striatal neurons in Huntington's disease.

  1985cited by this paper
• Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.

  1983cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids

  1976cited by this paper
• Huntington's disease

  1976cited by this paper

• Repurposing old molecules for new indications: Defining pillars of success from lessons in the past.

  2021cites this paper
• Celecoxib augmentation of escitalopram in treatment-resistant bipolar depression and the effects on Quinolinic Acid

  2019cites this paper
• Drug repurposing in neurological diseases: an integrated approach to reduce trial and error

  2019cites this paper
• Plant Metabolites and More Treating Various Ailments

  2017cites this paper
• Region-specific interneuronal degeneration in the human cerebral cortex in Huntington’s disease correlates with symptomatology

  2015cites this paper
• Huntington's disease: an update of therapeutic strategies.

  2015cites this paper
• Riluzole Ameliorates Harmaline-induced Tremor in Rat

  2014cites this paper
• A mitochondrial basis for Huntington’s disease: therapeutic prospects

  2014cites this paper
• Surveying the Landscape of Huntington's Disease Mechanisms, Measurements, and Medicines

  2013cites this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

  2012cites this paper
• Effects of riluzole on harmaline induced tremor and ataxia in rats: biochemical, histological and behavioral studies.

  2012cites this paper
• Pharmacologic approaches to the treatment of Huntington's disease

  2012cites this paper
• The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration

  2011cites this paper
• Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats.

  2011cites this paper
• The therapeutic potential of G-protein coupled receptors in Huntington's disease.

  2010cites this paper
• Molecular mechanisms and potential therapeutical targets in Huntington's disease.

  2010cites this paper
• Riluzole in Huntington's disease: a 3‐year, randomized controlled study

  2007cites this paper
• The corticostriatal pathway in Huntington's disease.

  2007cites this paper
• Huntington's disease: clinical characteristics, pathogenesis and therapies.

  2007cites this paper
• Ion channel diseases of the central nervous system.

  2006cites this paper
• Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

  2006cites this paper
• Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy)

  2005cites this paper
• Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole.

  2005cites this paper
• Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice

  2005cites this paper
• Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease.

  2004cites this paper
• The paradigm of Huntington’s disease: Therapeutic opportunities in neurodegeneration

  2004cites this paper
• Riluzole enhances the anti-seizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice.

  2004cites this paper
• Eine epidemiologische Studie im süddeutschen Raum

  2004cites this paper
• Interactions between riluzole and conventional antiepileptic drugs – a comparison of results obtained in the subthreshold method and isobolographic analysis

  2004cites this paper
• Dosage effects of riluzole in Huntington’s disease

  2003cites this paper
• Excitotoxicity in Huntington disease

  2003cites this paper
• Potential Mechanisms of Action of Lamotrigine in the Treatment of Bipolar Disorders

  2003cites this paper
• Therapeutics in Huntington’s Disease

  2002cites this paper
• Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence

  2002cites this paper
• The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.

  2000cites this paper
• Gabapentin-lactam (8-aza-spiro[5,4]decan-9-on; GBP-L) inhibits oxygen glucose deprivation-induced [3H]glutamate release and is a neuroprotective agent in a model of acute retinal ischemia

  2000cites this paper
• NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice.

  2000cites this paper
• Effects of riluzole on electrically evoked neurotransmitter release

  2000cites this paper
• The Neuroprotective Agent Riluzole Activates the Two P Domain K+ Channels TREK-1 and TRAAK

  2000cites this paper
• Protective Effects of Riluzole on Dopamine Neurons

  2000influential citation
• Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases.

  2000cites this paper
• Riluzole prevents ischemic spinal cord injury caused by aortic crossclamping.

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• The anti-inflammatory effects of quinolinic acid in the rat.

  1999cites this paper
• Riluzole therapy in Huntington's disease (HD)

  1999cites this paper
• The role of excitotoxicity in neurodegenerative disease: implications for therapy.

  1999cites this paper
• Antioxidative and Proapoptotic Effects of Riluzole on Cultured Cortical Neurons

  1999cites this paper
• [Riluzole as a treatment for amyotrophic lateral sclerosis].

  1998cites this paper
• Selective inhibition by riluzole of voltage-dependent sodium channels and catecholamine secretion in adrenal chromaffin cells

  1998cites this paper
• Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat

  1998cites this paper
• Riluzole reduces incidence of abnormal movements but not striatal cell death in a primate model of progressive striatal degeneration.

  1997cites this paper
• Time Course of Cerebral Edema after Traumatic Brain Injury in Rats: Effects of Riluzole and Mannitol

  1997cites this paper
• Effects of riluzole on the evolution of focal cerebral ischemia: a magnetic resonance imaging study

  1997cites this paper
• Riluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injury.

  1997cites this paper
• Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers.

  1997cites this paper
• Sodium channels and therapy of central nervous system diseases.

  1997cites this paper
• Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats.

  1997cites this paper
• Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA).

  1997cites this paper
• Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

  1996cites this paper
• A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Amyotrophic Lateral Sclerosis

  1996cites this paper
• Introduction 1. Huntingtin: the Huntington's Disease Protein 1.1. Huntingtin: an Overview

  year unknowncites this paper